The Peptide Patent Cliff: What 2027–2030 Means for the Industry
Between 2027 and 2030, patents on 14 peptide drugs worth $32B will expire. The GLP-1 biosimilar opportunity is immense but capital-intensive. Smart innovators are already shifting to next-generation molecules — the patent cliff is a stress test, not a crisis.